Ashling Wahner

David Rimm, MD, PhD, discusses ways that the use of ADCs in breast cancer might adapt to reflect emerging categories of detectable HER2 expression levels.

Jason Aboudi Mouabbi, MD, discusses challenges associated with diagnosing lobular breast cancer and the promising predictive value of FES-PET/CT imaging.

The FDA approved a monthly dosing schedule of amivantamab and hyaluronidase for the first-line treatment of patients with EGFR-mutated, advanced NSCLC.

David Rimm, MD, PhD, discusses whether ADCs should be considered similar to targeted therapy, or whether this class of agents is more akin to chemotherapy.

The FDA has issued REMS safety updates regarding the use of the denosumab biosimilars Enoby and Ospomyv for patients with breast and prostate cancers.

OncLive heard from experts across oncology specialties about the biggest updates from the 2026 Transplantation and Cellular Therapy Meetings.

Adoptive cell therapy elicited MRD-negative responses with low rates of GVHD and neurotoxicities in adult patients with high-risk B-ALL.

Orca-T/reduced-intensity conditioning was effective and decreased GVHD incidence vs PTCy/reduced-intensity conditioning in hematologic malignancies.

Prophylactic dexamethasone did not reduce the risk of developing DNT, nor the severity of DNT presentation, in cilta cel–treated myeloma with high ALC.

Acalabrutinib yielded durable organ-specific responses and a manageable safety profile in patients with steroid-refractory chronic graft-vs-host disease.

The FDA granted priority review to Dato-DXd for patients with first-line unresectable or metastatic TNBC who are not eligible to receive immunotherapy.

Fangfang Yan, PhD, discusses findings from a multi-omic analysis that identified mechanisms of pirtobrutinib resistance in mantle cell lymphoma.

The FDA has accepted a BLA seeking the approval of ivonescimab plus chemotherapy for EGFR-mutated, advanced, nonsquamous NSCLC after TKI progression.

The gremlin-1–directed monoclonal antibody ginisortamab showed early efficacy signals when combined with SOC therapy in patients with advanced GI tumors.

The FDA has approved daratumumab and hyaluronidase plus VRd for adult patients with newly diagnosed multiple myeloma who are not eligible for ASCT.

Treatment with first-line metronomic cyclophosphamide did not significantly improve TTF, PFS, or OS vs doxorubicin in advanced soft tissue sarcoma.

The NCCN guidelines recognize that MammaPrint can help identify a subset of patients with early-stage breast cancer likely to benefit from anthracycline-based therapy.

Phase 1 data demonstrate early safety and efficacy signals with targeting CBP/p300 in patients with solid tumors.

The combination of relacorilant and nab-paclitaxel generated an OS benefit vs nab-paclitaxel monotherapy in platinum-resistant ovarian cancer.

The INAVO123 trial is exploring frontline inavolisib plus a CDK4/6 inhibitor and letrozole in PIK3CA-mutant, hormone receptor–positive breast cancer.

Shaji Kumar, MD, discusses the mechanism of action of cevostamab, as well as data with a cevostamab-containing triplet in relapsed/refractory myeloma.

Lung cancer experts stress the importance of lung cancer screening and discuss ways that technological advances are transforming screening processes and outcomes.

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, discusses innovations in brain surgery and the importance of balancing oncological and functional outcomes.

The FDA has given priority review to a new drug application for gedatolisib in hormone receptor–positive, HER2-negative, PIK3CA wild-type advanced breast cancer.

Xiuning Le, MD, PhD, discusses the FDA approval of sevabertinib for pretreated, advanced, nonsquamous NSCLC with tumors harboring HER2 TKD mutations.

Lorenzo Falchi, MD, discusses the FDA approval of epcoritamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Treatment with nogapendekin alfa inbakicept plus BCG prolonged duration of complete response compared with BCG alone in patients with BCG-naive NMIBC.

Treatment with pembrolizumab after GI-6207 therapy did not generate therapeutic responses in patients with recurrent/metastatic medullary thyroid cancer.

Yue Wei, PhD, discussed the role of HMAs in platelet response in MDS and the clinical relevance of using a mouse model to investigate this approach.

Andrea Necchi, MD, dives into the details of the SunRISe-4 trial findings, implications, and ways that utDNA and ctDNA may operate as biomarkers in MIBC.